3 Reasons to Buy Viatris Stock, and 1 Reason to Sell
Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof returns in all economic environments, this company is just at the start of its tenure as an independent entity, having resulted from a spinoff by Pfizer in 2020.
But that doesn't mean Viatris is a bad option, especially for investors who want both a dividend payment and perhaps a bit of share price growth. Let's take a look at three reasons why this stock is worth owning, and one reason why some people might be interested in selling it rather than buying.
One big reason to buy Viatris stock soon is to get the advantage of its generous shareholder rewards policies. It pays a dividend that currently yields 4.9%, which is fairly high. While dividend growth hasn't been significant since the company became an independent entity in 2021, with its payout rising by around 9%, it could pick up the pace as soon as there's more cash to go around.
Source Fool.com
Viatris Inc. Aktie
Die Viatris Inc. Aktie hat zu wenige Einschätzungen, um eine klare Tendenz abzulesen.
Bei einem Kursziel von 12 € für Viatris Inc. deutet sich eine Steigerung von über 20% vom aktuellen Kurs von 9.71 € an.
